<DOC>
	<DOCNO>NCT02967523</DOCNO>
	<brief_summary>This project involve collection analysis retrospective prospective data patient diagnose hepatocellular carcinoma ( HCC ) Surefire Precision Infusion System used/will use deliver transarterial chemoembolization doxorubicin-eluting bead ( DEB-TACE ) . The purpose compare tumor medical response real-world set well identify potential area future clinical research .</brief_summary>
	<brief_title>Surefire Precision Infusion System Registry</brief_title>
	<detailed_description>Conventional transarterial chemoembolization lipiodol/doxorubicin ( cTACE ) know prolong survival compare supportive therapy certain patient unresectable HCC , include patient unilateral portal vein invasion ( PVI ) . The best result cTACE occur dose deliver highly targeted manner tumor . Dense accumulation embolic spheres lipiodol tumor document computed tomography ( CT ) show improved outcome . However , standard endhole catheter , achieve maximum delivery embolic agent significantly limit development stasis , non-target delivery subsequent non-target injury . Thus , procedure perform endhole catheter , significant variability delivery agent entirely dependent flow pattern target tumor . Therefore , current technique result various degree embolization variability dosage angiographic endpoint . DEB-TACE relatively new modality associate favorable systemic doxorubicin exposure/toxicity liver-specific toxicity compare cTACE . It currently utilize : ( 1 ) patient unresectable HCC ; ( 2 ) patient meet Milan Criteria currently liver transplantation list ; ( 3 ) downstaging patient Milan Criteria possible liver transplantation .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Patients undergone undergo DEBTACE HCC deliver Surefire® Precision Infusion System Patients age 18 year old Diagnosis HCC Has discrete hepatic artery ( ) feed vessel diameter ( ) vessel ≥ 1.5 mm Contraindications doxorubicin administration Vessels provide flow tumor &lt; 1.5 mm diameter ( ) Patients unable provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>DEB-TACE</keyword>
</DOC>